Tags

Type your tag names separated by a space and hit enter

Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
J Antimicrob Chemother. 1999 Oct; 44(4):515-23.JA

Abstract

The efficacy and safety of grepafloxacin were compared with clarithromycin in a randomized, double-blind, multicentre clinical trial of 805 patients with acute bacterial exacerbations of chronic bronchitis (ABECB). Patients were randomized to receive grepafloxacin 400 mg od for either 5 (n = 273) or 10 days (n = 268) or clarithromycin 250 mg bd for 10 days (n = 261). Patients were assessed pre-treatment, 3-5 days during treatment, 1-3 days post-treatment and at follow-up (21-28 days post-treatment). The clinical success rates for the evaluable patients were 91% in the 5 day grepafloxacin group, 95% in the 10 day grepafloxacin group and 86% in the clarithromycin group. At follow-up, respective rates were 72%, 81% and 73%. A total of 513 pathogens were isolated from the pre-treatment sputum specimens of 400 (49%) patients. The primary pathogens were Haemophilus influenzae (36% of isolates), Haemophilus parainfluenzae (27%), Moraxella catarrhalis (12%), Streptococcus pneumoniae (11%) and Staphylococcus aureus (3%). Pathogens were eradicated or presumed eradicated at post-treatment in 85%, 91% and 58% of evaluable patients treated with grepafloxacin for 5 days, grepafloxacin 10 days and clarithromycin 10 days, respectively. The eradication rates in both grepafloxacin groups were significantly greater than the clarithromycin group (P<0.001). All treatments were well tolerated and incidence of drug-related adverse events in each group was comparable. This study demonstrates that both a 5 and a 10 day regimen of grepafloxacin 400 mg od are as clinically and bacteriologically effective as in the treatment of ABECB clarithromycin 250 mg bd. for 10 days.

Authors+Show Affiliations

Baillieston Health Centre, Glasgow, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10588313

Citation

Langan, C E., et al. "Randomized, Double-blind Study of Short-course (5 Day) Grepafloxacin Versus 10 Day Clarithromycin in Patients With Acute Bacterial Exacerbations of Chronic Bronchitis." The Journal of Antimicrobial Chemotherapy, vol. 44, no. 4, 1999, pp. 515-23.
Langan CE, Zuck P, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44(4):515-23.
Langan, C. E., Zuck, P., Vogel, F., McIvor, A., Peirzchala, W., Smakal, M., Staley, H., & Marr, C. (1999). Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. The Journal of Antimicrobial Chemotherapy, 44(4), 515-23.
Langan CE, et al. Randomized, Double-blind Study of Short-course (5 Day) Grepafloxacin Versus 10 Day Clarithromycin in Patients With Acute Bacterial Exacerbations of Chronic Bronchitis. J Antimicrob Chemother. 1999;44(4):515-23. PubMed PMID: 10588313.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. AU - Langan,C E, AU - Zuck,P, AU - Vogel,F, AU - McIvor,A, AU - Peirzchala,W, AU - Smakal,M, AU - Staley,H, AU - Marr,C, PY - 1999/12/10/pubmed PY - 1999/12/10/medline PY - 1999/12/10/entrez SP - 515 EP - 23 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 44 IS - 4 N2 - The efficacy and safety of grepafloxacin were compared with clarithromycin in a randomized, double-blind, multicentre clinical trial of 805 patients with acute bacterial exacerbations of chronic bronchitis (ABECB). Patients were randomized to receive grepafloxacin 400 mg od for either 5 (n = 273) or 10 days (n = 268) or clarithromycin 250 mg bd for 10 days (n = 261). Patients were assessed pre-treatment, 3-5 days during treatment, 1-3 days post-treatment and at follow-up (21-28 days post-treatment). The clinical success rates for the evaluable patients were 91% in the 5 day grepafloxacin group, 95% in the 10 day grepafloxacin group and 86% in the clarithromycin group. At follow-up, respective rates were 72%, 81% and 73%. A total of 513 pathogens were isolated from the pre-treatment sputum specimens of 400 (49%) patients. The primary pathogens were Haemophilus influenzae (36% of isolates), Haemophilus parainfluenzae (27%), Moraxella catarrhalis (12%), Streptococcus pneumoniae (11%) and Staphylococcus aureus (3%). Pathogens were eradicated or presumed eradicated at post-treatment in 85%, 91% and 58% of evaluable patients treated with grepafloxacin for 5 days, grepafloxacin 10 days and clarithromycin 10 days, respectively. The eradication rates in both grepafloxacin groups were significantly greater than the clarithromycin group (P<0.001). All treatments were well tolerated and incidence of drug-related adverse events in each group was comparable. This study demonstrates that both a 5 and a 10 day regimen of grepafloxacin 400 mg od are as clinically and bacteriologically effective as in the treatment of ABECB clarithromycin 250 mg bd. for 10 days. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/10588313/Randomized_double_blind_study_of_short_course__5_day__grepafloxacin_versus_10_day_clarithromycin_in_patients_with_acute_bacterial_exacerbations_of_chronic_bronchitis_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/44.4.515 DB - PRIME DP - Unbound Medicine ER -